New vascular disrupting agents in upper gastrointestinal malignancies

A. E. Quatrale, L. Porcelli, A. Gnoni, G. Numico, A. Paradiso, A. Azzariti

Research output: Contribution to journalArticlepeer-review


Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive tumour cell death. Tumour vascular disrupting agents (VDAs) are a new class of cancer therapies that target the existing vasculature of tumours, taking advantage of the relative instability of tumour vasculature and its supporting structures. Treatment with VDAs induces a rapid collapse and regression of tumour vessels, with a consequent deprivation of blood and oxygen which leads to ischemic or hemorrhagic necrosis of the tumour. In this review, an overview of the most recently developed vascular disrupting agents is reported, focusing on the biological effects exerted by these compounds on endothelial cells and tumour vasculature, potentially effective in the treatment of several malignancies including upper gastrointestinal tumours. In particular, we have focused on the antimitotic agent combretastatin and its numerous synthetic analogues such as combretastatin A-4-phosphate, OXI4503, and AVE8062, and on the colchicine analogue ZD6126.

Original languageEnglish
Pages (from-to)1039-1049
Number of pages11
JournalCurrent Medicinal Chemistry
Issue number8
Publication statusPublished - 2014


  • Gastrointestinal cancers
  • Upper gastrointestinal malignancies
  • Vascular disrupting agents

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'New vascular disrupting agents in upper gastrointestinal malignancies'. Together they form a unique fingerprint.

Cite this